Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542161 · ClinicalTrials.gov registry record · Phase 2
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
A Phase 2 study of Chronic Fatigue Syndrome and Myalgic Encephalomyelitis, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 1
- Study location
NCT04542161: Recruiting Phase 2 study of Chronic Fatigue Syndrome and Myalgic Encephalomyelitis, sponsored by Weill Medical College of Cornell University.
NCT04542161 is a Phase 2 study of Chronic Fatigue Syndrome and Myalgic Encephalomyelitis that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 95 participants, below the 7,241-participant average among 14 other Chronic Fatigue Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04542161, a Phase 2 study of Chronic Fatigue Syndrome and Myalgic Encephalomyelitis, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) is an unexplained multisymptom/multisystem disorder for which there are currently no validated treatments. The present exploratory clinical trial aims to advance our understand of the mechanisms of in situ GSH synthesis control through assessment of the response of brain GSH and plasma markers of oxidative stress to different doses of NAC in comparison to placebo, as a potential treatment for ME/CFS that would provide neuroprotection against oxidative stress by restoring cortical GSH reserves. If successful, this exploratory clinical trial would address a significant public health concern by shedding new light onto the mechanisms of action of NAC in brain GSH restoration, which could open a new avenue for the development of potentially effective treatments for a disorder, ME/CFS, that currently has none.
Primary Outcome
Levels of occipital cortex GSH, as measured in vivo with 1H MRS
Conditions Studied
Interventions
- DRUG NAC 900mg/day
- DRUG NAC 3600mg/day
- DRUG NAC 0mg/day (Placebo)
Study Locations (1)
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
What NCT04542161 shows while recruiting
NCT04542161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 7,241-participant average among 14 other Chronic Fatigue Syndrome trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Chronic Fatigue Syndrome appearing as the primary indexed condition, and to 3 interventions - of which NAC 900mg/day is the first listed.
NCT04542161 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04542161 about?
NCT04542161 is a clinical study titled "Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) is an unexplained multisymptom/multisystem disorder for which there are currently no validated treatments. The present exploratory clinical trial aims to advance our understand of the mechanisms of in situ GSH synthesis control through asse...
What is the current status of trial NCT04542161?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2020-09-01. Estimated completion is 2026-04-30.
What conditions does trial NCT04542161 study?
This clinical trial studies the following conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis.
What interventions are being tested in trial NCT04542161?
The interventions under investigation include: NAC 900mg/day (DRUG), NAC 3600mg/day (DRUG), NAC 0mg/day (Placebo) (DRUG).
Who is sponsoring clinical trial NCT04542161?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04542161 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Fatigue Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04542161's enrollment target sits among peer trials
95 7th of 14 higher than 8 of 14 other Chronic Fatigue Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Fatigue Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
COMPLETED · Phase 2
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
RECRUITING · Phase 1
-
Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS
RECRUITING · NA
-
tVNS in Long COVID-19
RECRUITING · NA
-
The Long COVID-19 Wearable Device Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI